Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome

Discontinuation of Eculizumab Treatment in Atypical Hemolytic Uremic Syndrome: An Update

(2015) Gianluigi Ardissino et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Soluble C5b-9 as a Biomarker for Complement Activation in Atypical Hemolytic Uremic Syndrome

(2015) Fengxiao Bu et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS

(2015) R. Cofiell et al.   BLOOD

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

(2015) Christoph Licht et al.   KIDNEY INTERNATIONAL

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome

(2014) M. Cugno et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome

(2013) M. Le Quintrec et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults

(2013) V. Fremeaux-Bacchi et al.   Clinical Journal of the American Society of Nephrology

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

(2013) C.M. Legendre et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation

(2012) J. Zuber et al.   AMERICAN JOURNAL OF TRANSPLANTATION

UPDATE OF THE DUTCH MANUAL FOR COSTING IN ECONOMIC EVALUATIONS

(2012) Siok Swan Tan et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

A Systematic Review and Meta-Analysis of Utility-Based Quality of Life in Chronic Kidney Disease Treatments

(2012) Melanie Wyld et al.   PLOS MEDICINE